US-HEALTH-VIRUS

In this photo illustration a Gilead logo is displayed on a smartphone next to a screen showing a coronavirus graphic on March 25, 2020 in Arlington, Virginia. - Gilead announced on March 25, 2020 that it has submitted a request to the Food and Drug Administration to rescind the exclusive marketing rights it had secured for remdesivir, an antiviral drug that shows promise in treating Covid-19, the disease caused by the new coronavirus. (Photo by Olivier DOULIERY / AFP) (Photo by OLIVIER DOULIERY/AFP via Getty Images)
In this photo illustration a Gilead logo is displayed on a smartphone next to a screen showing a coronavirus graphic on March 25, 2020 in Arlington, Virginia. - Gilead announced on March 25, 2020 that it has submitted a request to the Food and Drug Administration to rescind the exclusive marketing rights it had secured for remdesivir, an antiviral drug that shows promise in treating Covid-19, the disease caused by the new coronavirus. (Photo by Olivier DOULIERY / AFP) (Photo by OLIVIER DOULIERY/AFP via Getty Images)
US-HEALTH-VIRUS
COMPRAR LICENCIA
¿Cómo puedo usar esta imagen?
475,00 €
EUR

DETALLES

Restricciones:
Póngase en contacto con su oficina local para conocer todos los usos con fines comerciales o promocionales. Derechos editoriales plenos en Reino Unido, EE.UU., Irlanda, Italia, España y Canadá (excepto Québec). Si desea conocer los derechos editoriales restringidos en otro país, llame a su oficina local.
Crédito:
OLIVIER DOULIERY / Colaborador
Editorial n.º:
1208237136
Colección:
AFP
Fecha de creación:
25 de marzo de 2020
Fecha de subida:
Tipo de licencia:
Inf. de autorización:
No se cuenta con autorizaciones. Más información
Fuente:
AFP
Código de barras:
AFP
Nombre del objeto:
AFP_1Q67SP
Tamaño máx. archivo:
4000 x 2507 px (33,87 x 21,23 cm) - 300 dpi - 2 MB